Cargando…

Encephalopathy after COVID-19 vaccination during treatment with nivolumab: A case report

Vaccination is useful for the prevention of COVID-19 and is recommended for everyone, especially people with a weakened immune system. However, various neurological complications have been reported following vaccination. Here, we report the case of a 25 years-old, Japanese man, who presented with ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Takenaka, Megumi, Nakamori, Masahiro, Ishikawa, Rouyi, Aoki, Shiro, Maruyama, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928746/
https://www.ncbi.nlm.nih.gov/pubmed/36841006
http://dx.doi.org/10.1016/j.clineuro.2023.107632
_version_ 1784888709049483264
author Takenaka, Megumi
Nakamori, Masahiro
Ishikawa, Rouyi
Aoki, Shiro
Maruyama, Hirofumi
author_facet Takenaka, Megumi
Nakamori, Masahiro
Ishikawa, Rouyi
Aoki, Shiro
Maruyama, Hirofumi
author_sort Takenaka, Megumi
collection PubMed
description Vaccination is useful for the prevention of COVID-19 and is recommended for everyone, especially people with a weakened immune system. However, various neurological complications have been reported following vaccination. Here, we report the case of a 25 years-old, Japanese man, who presented with acute encephalopathy two days after the second dose of the COVID-19 vaccine. He had been treated with nivolumab, a medication used to treat cancer. He had a high fever and was confused upon admission, and the antibody test was positive for anti-myelin oligodendrocyte glycoproteins. Abnormal signal intensity at the splenium corporis callosi was observed on diffusion-weighted imaging of the brain. We diagnosed him with autoimmune encephalitis and initiated intravenous methylprednisolone, after which, the patient’s symptoms rapidly subsided.
format Online
Article
Text
id pubmed-9928746
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-99287462023-02-15 Encephalopathy after COVID-19 vaccination during treatment with nivolumab: A case report Takenaka, Megumi Nakamori, Masahiro Ishikawa, Rouyi Aoki, Shiro Maruyama, Hirofumi Clin Neurol Neurosurg Case Report Vaccination is useful for the prevention of COVID-19 and is recommended for everyone, especially people with a weakened immune system. However, various neurological complications have been reported following vaccination. Here, we report the case of a 25 years-old, Japanese man, who presented with acute encephalopathy two days after the second dose of the COVID-19 vaccine. He had been treated with nivolumab, a medication used to treat cancer. He had a high fever and was confused upon admission, and the antibody test was positive for anti-myelin oligodendrocyte glycoproteins. Abnormal signal intensity at the splenium corporis callosi was observed on diffusion-weighted imaging of the brain. We diagnosed him with autoimmune encephalitis and initiated intravenous methylprednisolone, after which, the patient’s symptoms rapidly subsided. Elsevier B.V. 2023-03 2023-02-15 /pmc/articles/PMC9928746/ /pubmed/36841006 http://dx.doi.org/10.1016/j.clineuro.2023.107632 Text en © 2023 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Case Report
Takenaka, Megumi
Nakamori, Masahiro
Ishikawa, Rouyi
Aoki, Shiro
Maruyama, Hirofumi
Encephalopathy after COVID-19 vaccination during treatment with nivolumab: A case report
title Encephalopathy after COVID-19 vaccination during treatment with nivolumab: A case report
title_full Encephalopathy after COVID-19 vaccination during treatment with nivolumab: A case report
title_fullStr Encephalopathy after COVID-19 vaccination during treatment with nivolumab: A case report
title_full_unstemmed Encephalopathy after COVID-19 vaccination during treatment with nivolumab: A case report
title_short Encephalopathy after COVID-19 vaccination during treatment with nivolumab: A case report
title_sort encephalopathy after covid-19 vaccination during treatment with nivolumab: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928746/
https://www.ncbi.nlm.nih.gov/pubmed/36841006
http://dx.doi.org/10.1016/j.clineuro.2023.107632
work_keys_str_mv AT takenakamegumi encephalopathyaftercovid19vaccinationduringtreatmentwithnivolumabacasereport
AT nakamorimasahiro encephalopathyaftercovid19vaccinationduringtreatmentwithnivolumabacasereport
AT ishikawarouyi encephalopathyaftercovid19vaccinationduringtreatmentwithnivolumabacasereport
AT aokishiro encephalopathyaftercovid19vaccinationduringtreatmentwithnivolumabacasereport
AT maruyamahirofumi encephalopathyaftercovid19vaccinationduringtreatmentwithnivolumabacasereport